Cingulate
CING | NASDAQ
$3.75
-$0.55 (-12.79%)
At close: Nov 16, 2026, 4:00 PM ET
$3.71
-$0.04 (-1.07%)
After-hours:
Nov 16, 2026, 7:53 PM ET
-12.79%
(1D)No price chart data available for 1D timeframe.
Rating
39
+3.0 ptsFundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #552/1021 (Top 54%)
Key Statistics
Market Data
Market Cap $54.53M
1D Range
3.65 4.12
52W Range
3.33 11.66
Valuation (TTM)
PE -0.89
PB 0.00
EV/EBITDA N/A
Valuation (NTM)
Forward PE N/A
Forward PEG 0.02
Price Target $9.00
Cash Flow
FCF Yield -37428.2%
SBC Adj. FCF Yield -40525.5%
SBC Impact -8.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 96.4% |
71.5%
FCF 3Y | 5Y -149.6% |
-99.6%
Returns
ROA -27.5%
ROE -149.0%
ROIC -0.1%
Financial Health
Net Cash
$22.02B
Current Ratio 3,904.28
Interest Coverage 25.61
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Cingulate Inc. is a biopharmaceutical enterprise currently in its clinical development phase, dedicated to devising therapeutic options for attention-deficit/hyperactivity disorder (ADHD). Leading its...
Sector Healthcare
Industry Biotechnology
Employees 14
IPO Date Dec 8, 2021
Website www.cingulate.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$9.00
Upside
+140.00%
Buy (3)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove CING